KZIA
NASDAQKazia Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$13.58+0.63 (+4.91%)
02:00 PM07:45 PM
News · 26 weeks680%
2026-02-222026-08-16
Mix3390d
- SEC Filings15(45%)
- Insider11(33%)
- Other3(9%)
- Analyst3(9%)
- Leadership1(3%)
Latest news
25 items- ANALYSTCanaccord Genuity initiated coverage on Kazia Therapeutics with a new price targetCanaccord Genuity initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $29.00
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- PRKazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast CancerSYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the filing of a provisional patent application supporting a novel therapeutic strategy designed to prevent metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer (TNBC). The patent filing is supported by new preclinical findings from a model designed to replicate high-risk early-stage TNBC. In the model, standard treatment —neoadjuvant chemotherapy, anti-PD-1 immunotherapy and surgical resection — followed
- INSIDERSEC Form 4 filed by Director Coffey Steven R. S.4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Friend John E. Ii4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 4 filed by VP, Finance and Controller Bonacorda Jeffrey4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 4 filed by Director Davidson Ebru4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 4 filed by Director, CMC Cain David4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 4 filed by Director Apple Robert F4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- ANALYSTBTIG Research initiated coverage on Kazia Therapeutics with a new price targetBTIG Research initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $34.00
- INSIDERSEC Form 4 filed by Chief Financial Officer Levine James E.4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Rao Sudha4 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- INSIDERSEC Form 3 filed by new insider Levine James E.3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- ANALYSTLake Street initiated coverage on Kazia Therapeutics with a new price targetLake Street initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $32.00
- INSIDERSEC Form 3 filed by new insider Davidson Ebru3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- PRThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
KZIA FAQ
6 questionsWhat does Kazia Therapeutics Limited do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Where does KZIA stock trade?
Kazia Therapeutics Limited (KZIA) is listed on NASDAQ.What sector and industry is KZIA in?
Kazia Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KZIA?
Kazia Therapeutics Limited has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $2900.00 price target on 2026-08-13.What companies are similar to KZIA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KZIA side-by-side with any of them on Quantisnow.How can I track KZIA on Quantisnow?
Quantisnow aggregates Kazia Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KZIA to receive live email and push alerts on every new disclosure.